{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-22-004769","form_type":"8-K","ticker":"MBRX","cik":"0001659617","company_name":"Moleculin Biotech, Inc.","filed_at":"2022-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.669023+00:00","generated_at":"2026-06-27T03:04:33.404632+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Moleculin appoints Joy Yan, M.D., Ph.D. to Board of Directors","bullets":["Appointment effective March 1, 2022; Dr. Yan will serve as an independent director.","Compensation includes $40,000 annual cash retainer and 10-year option for 6,667 shares vesting over 3 years.","Dr. Yan brings experience from Bristol Myers Squibb, Janssen, Bayer; led development of nivolumab and ipilimumab.","No board committee assignments at this time.","Press release issued March 1, 2022; standard indemnification agreement executed."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-22-004769","json":"https://secwatch.observer/filing/0001437749-22-004769.json","markdown":"https://secwatch.observer/filing/0001437749-22-004769.md","text":"https://secwatch.observer/filing/0001437749-22-004769.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659617/000143774922004769/0001437749-22-004769-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659617/000143774922004769/mbrx20220224_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T03:04:33.404632+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"021beb93c1","claim":"Joy Yan was appointed as Independent Director at Moleculin Biotech, Inc..","evidence_excerpt":"On March 1, 2022, the Board of Directors of Moleculin Biotech, Inc. (the “Company”) appointed Joy Yan as an independent member of the Company’s Board of Directors, effective on such date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1659617/000143774922004769/0001437749-22-004769-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Independent Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}